Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion



Genome-wide association studies have shown that variation in MTNR1B (melatonin receptor 1B) is associated with insulin and glucose concentrations. Here we show that the risk genotype of this SNP predicts future type 2 diabetes (T2D) in two large prospective studies. Specifically, the risk genotype was associated with impairment of early insulin response to both oral and intravenous glucose and with faster deterioration of insulin secretion over time. We also show that the MTNR1B mRNA is expressed in human islets, and immunocytochemistry confirms that it is primarily localized in β cells in islets. Nondiabetic individuals carrying the risk allele and individuals with T2D showed increased expression of the receptor in islets. Insulin release from clonal β cells in response to glucose was inhibited in the presence of melatonin. These data suggest that the circulating hormone melatonin, which is predominantly released from the pineal gland in the brain, is involved in the pathogenesis of T2D. Given the increased expression of MTNR1B in individuals at risk of T2D, the pathogenic effects are likely exerted via a direct inhibitory effect on β cells. In view of these results, blocking the melatonin ligand-receptor system could be a therapeutic avenue in T2D.

  • Subscribe to Nature Genetics for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, & Novartis Institutes of BioMedical Research, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331–1336 (2007).

  2. 2.

    et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341–1345 (2007).

  3. 3.

    et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881–885 (2007).

  4. 4.

    et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40, 638–645 (2008).

  5. 5.

    et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336–1341 (2007).

  6. 6.

    et al. Variants in MTNR1B influence fasting glucose levels and risk of type 2 diabetes. Nat. Genet. advance online publication, doi:10.1038/ng.290 (7 December 2008).

  7. 7.

    Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 44, 26–40 (2008).

  8. 8.

    Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem. J. 31, 1–12 (1999).

  9. 9.

    , , & Evidence for a circadian rhythm of insulin secretion. Am. J. Physiol. 271, E246–E252 (1996).

  10. 10.

    et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 85, 335–353 (2008).

  11. 11.

    & Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J. Pineal Res. 42, 105–106 (2007).

  12. 12.

    et al. Function and expression of melatonin receptors on human pancreatic islets. J. Pineal Res. 44, 273–279 (2008).

  13. 13.

    et al. Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care 21, 949–958 (1998).

  14. 14.

    , , , & Patterns of growth among children who later develop type 2 diabetes or its risk factors. Diabetologia 49, 2853–2858 (2006).

  15. 15.

    et al. Gene expression of purified beta-cell tissue obtained from human pancreas with laser capture microdissection. J. Clin. Endocrinol. Metab. 93, 1046–1053 (2008).

  16. 16.

    , & Parallel signaling pathways of melatonin in the pancreatic beta-cell. J. Pineal Res. 40, 184–191 (2006).

  17. 17.

    et al. Melatonin and type 2 diabetes - a possible link? J. Pineal Res. 42, 350–358 (2007).

  18. 18.

    et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J. Intern. Med. 247, 19–29 (2000).

  19. 19.

    et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359, 2220–2232 (2008).

  20. 20.

    et al. Genetic prediction of future type 2 diabetes. PLoS Med. 2, e345 (2005).

  21. 21.

    et al. Predictors of and longitudinal changes in insulin sensitivity & secretion preceding onset of type 2 diabetes. Diabetes 54, 166–174 (2005).

  22. 22.

    , , & Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 42, 250–256 (1993).

  23. 23.

    , & Modified protocols improve insulin sensitivity estimation using the minimal model. Am. J. Physiol. 253, E595–E602 (1987).

  24. 24.

    , , & Quantitative estimation of insulin sensitivity. Am. J. Physiol. 236, E667–E677 (1979).

  25. 25.

    , , , & Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J. Clin. Invest. 74, 1318–1328 (1984).

  26. 26.

    & Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).

  27. 27.

    et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am. J. Epidemiol. 151, 190–198 (2000).

  28. 28.

    , , , & CART regulates islet hormone secretion and is expressed in the beta-cells of type 2 diabetic rats. Diabetes 55, 305–311 (2006).

  29. 29.

    et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54, 727–735 (2005).

  30. 30.

    & Family-based association tests for genomewide association scans. Am. J. Hum. Genet. 81, 913–926 (2007).

Download references


The DGI study was supported by a grant from Novartis.

Studies in Malmoe were supported by grants from the Swedish Research Council, including a Linné grant (No. 31475113580), the Diabetes Programme at Lund University, the Påhlsson Foundation, the Heart and Lung Foundation, the Wallenberg Foundation, the Swedish Diabetes Research Society, the Crafoord Foundation, Swedish Medical Society, Swedish Royal Physiographic Society, a Nordic Centre of Excellence Grant in Disease Genetics, the Finnish Diabetes Research Society, the Sigrid Juselius Foundation, Folkhälsan Research Foundation, Novo Nordisk Foundation, the European Network of Genomic and Genetic Epidemiology (ENGAGE), the Wallenberg Foundation, the European Foundation for the Study of Diabetes (EFSD) and the Human Tissue facility at the Lund University Diabetes Center. Studies in human islets were supported in part by the Italian Ministry of University and Research (PRIN 2007-2008) and the European Community (LSHM-CT-2006-518153).

Pancreatic islets at US National Institutes of Health were obtained through the ICR Basic Science Islet Distribution Program (City of Hope Hospital, Joslin Diabetes Center, Northwestern University, Southern California Islet Consortium, University of Alabama Birmingham, University of Illinois, University of Miami, University of Minnesota, University of Pennsylvania, University of Wisconsin and Washington University), the Juvenile Diabetes Research Foundation Islet Resources (Washington University) and the National Disease Resource Interchange (NDRI).

The FUSION study would like to thank the many research volunteers who generously participated in the various studies represented in FUSION. We also thank A.J. Swift, M. Morken, P.S. Chines and N. Narisu for genotying and informatics support. Support for FUSION was provided by the following: NIH grant DK062370 (M. Boehnke), American Diabetes Association research grant 1-05-RA-140 (R.M.W.), DK072193 (K.L. Mohlke) and National Human Genome Research Institute intramural project number 1 Z01 HG000024 (F.S. Collins). The METSIM study was supported by Academy of Finland grant 124243 (M.L.).

Author information


  1. Unit of Diabetes and Endocrinology, Department of Clinical Sciences in Malmoe, Lund University Diabetes Centre, University Hospital, Malmoe 20520, Sweden.

    • Valeriya Lyssenko
    • , Anna Jonsson
    •  & Leif Groop
  2. Unit of Molecular Metabolism, Department of Clinical Sciences in Malmoe, Lund University Diabetes Centre, Malmoe 20502, Sweden.

    • Cecilia L F Nagorny
    • , Peter Spégel
    •  & Hindrik Mulder
  3. Genome Technology Branch, National Human Genome Research Institute, Bethesda, Maryland 20892, USA.

    • Michael R Erdos
  4. Unit of Neuroendocrine Cell Biology, Department of Experimental Medical Science, Lund University, Lund 22184, Sweden.

    • Nils Wierup
    •  & Frank Sundler
  5. Department of Endocrinology and Metabolism, University of Pisa, Pisa 56124, Italy.

    • Marco Bugliani
    • , Nicolo Pulizzi
    •  & Piero Marchetti
  6. Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.

    • Richa Saxena
    •  & David Altshuler
  7. Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

    • Richa Saxena
    •  & David Altshuler
  8. Unit for Diabetes and Celiac Disease, Department of Clinical Sciences in Malmoe, Lund University Diabetes Centre, Malmoe 20502, Sweden.

    • Malin Fex
  9. Folkhalsan Research Centre, Helsinki 00251, Finland.

    • Bo Isomaa
    •  & Tiinamaija Tuomi
  10. Department of Medicine, Helsinki University Central Hospital, and Research Program of Molecular Medicine, University of Helsinki, Helsinki 00140, Finland.

    • Tiinamaija Tuomi
    •  & Leif Groop
  11. Department of Clinical Sciences, Medicine, Lund University, Malmoe 20502, Sweden.

    • Peter Nilsson
  12. Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio 70210, Finland.

    • Johanna Kuusisto
    •  & Markku Laakso
  13. Diabetes Unit, Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki 00300, Finland.

    • Jaakko Tuomilehto
  14. Department of Public Health, University of Helsinki, Helsinki 00014, Finland.

    • Jaakko Tuomilehto
  15. South Ostrobothnia Central Hospital, Senäjoki 60220, Finland.

    • Jaakko Tuomilehto
  16. Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109, USA.

    • Michael Boehnke
    •  & Anne U Jackson
  17. National Public Health Institute, Helsinki 00300, Finland.

    • Johan G Eriksson
  18. Department of General Practice and Primary Health Care, University of Helsinki, Helsinki 00014, Finland.

    • Johan G Eriksson
  19. Department of Preventive Medicine, University of Southern California, Los Angeles, California 90033, USA.

    • Richard M Watanabe
  20. Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

    • Richard M Watanabe


  1. Search for Valeriya Lyssenko in:

  2. Search for Cecilia L F Nagorny in:

  3. Search for Michael R Erdos in:

  4. Search for Nils Wierup in:

  5. Search for Anna Jonsson in:

  6. Search for Peter Spégel in:

  7. Search for Marco Bugliani in:

  8. Search for Richa Saxena in:

  9. Search for Malin Fex in:

  10. Search for Nicolo Pulizzi in:

  11. Search for Bo Isomaa in:

  12. Search for Tiinamaija Tuomi in:

  13. Search for Peter Nilsson in:

  14. Search for Johanna Kuusisto in:

  15. Search for Jaakko Tuomilehto in:

  16. Search for Michael Boehnke in:

  17. Search for David Altshuler in:

  18. Search for Frank Sundler in:

  19. Search for Johan G Eriksson in:

  20. Search for Anne U Jackson in:

  21. Search for Markku Laakso in:

  22. Search for Piero Marchetti in:

  23. Search for Richard M Watanabe in:

  24. Search for Hindrik Mulder in:

  25. Search for Leif Groop in:


V.L.: DGI GWAS, data analysis and draft of the report. C.L.F.N., M.R.E.: in vitro expression experiments and analysis, and draft of the report. N.W.: immunocytochemistry. A.J.: genotyping and data analysis. P.S.: in vitro expression experiments. M. Bugliani: microarray and human islets experiments. R.S.: DGI GWAS analysis. M.F.: in vitro physiology. N.P.: genotyping. B.I., T.T.: phenotyping in the Botnia study. P.N.: phenotyping in the Malmoe study. J.K.: data analysis in METSIM study. J.T.: phenotyping in the FUSION study. M. Boehnke: PI of the FUSION study. D.A.: PI of the DGI study. F.S.: immunocytochemistry. J.G.E.: phenotyping in the Helsinki Birth Cohort Study. A.U.J.: FUSION GWAS and data analysis. M.L.: PI of the METSIM study. P.M.: microarray and human islets experiments. R.M.W.: FUSION GWAS analysis. H.M.: design and supervision of in vitro study experiments and draft of the report. L.G. designed and supervised all parts of the study and drafted the report. All researchers took part in the revision of the report and approved the final version.

Corresponding author

Correspondence to Leif Groop.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figure 1